INV274 is the project name for our vaccine candidate against infections caused by Streptococcus suis.
Antigens for a vaccine against Streptococcus suis have been identified and used in studies of weaned piglets given experimental infection with S. suis bacteria. The company have been able to identify a vaccine candidate, INV274, with promising results which form the basis for further efficacy studies. The vaccine would provide broad protection against different serotypes of S. suis due to the fact that the antigens contained in the vaccine are not linked to only a limited number of serogroups.
This project has been awarded funding through the Eurostars-2 program for further development. The project phase that Intervacc, together with Moredun Scientific, now has been granted funding for, includes funds for implementing a number of important development steps including pre-clinical efficacy studies in piglets, antibody analysis and vaccination also of pregnant sows.